Anastrozole 1 MG
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-20-R-0065
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
The Defense Logistics Agency (DLA) Troop Support has issued a solicitation, identified as SPE2D2-20-R-0065, for the supply of Anastrozole 1 MG tablets. This procurement is part of a national contract aimed at ensuring a reliable and consistent supply of this pharmaceutical product, which is commonly used in the treatment of hormone receptor-positive breast cancer. The scope of this contract encompasses the manufacturing and delivery of Anastrozole 1 MG tablets in accordance with federal requirements and quality standards.
Recent modifications to the contract include the issuance of Modification P00008, which invokes option year 4, thereby extending the contract period and reaffirming the government’s ongoing need for this medication. Additionally, Modification P00007 incorporates Federal Acquisition Regulation (FAR) clause 52.204-30, which pertains to the Federal Acquisition Supply Chain Security Act Orders. This inclusion underscores the government’s commitment to supply chain security and compliance with federal acquisition policies.
The procurement falls under NAICS code 325412, which covers Pharmaceutical Preparation Manufacturing, and is classified under Product Service Code (PSC) 6505, indicating drugs and biologicals. The contracting activity is managed by DLA Troop Support, a federal office responsible for providing medical supplies to military and federal agencies. The primary point of contact for this solicitation is Kyle Lewicki, who can be reached at [email protected] or by phone at 215-737-3696.
This solicitation is currently active and was most recently posted on August 15, 2024. Interested parties should note that the original response date was May 28, 2020, which may indicate that this is a continuing or recurring requirement rather than a new opportunity. The solicitation and its associated modifications are accessible via the SAM.gov portal, where nine attachments provide further details on requirements and terms.
Contractors considering this opportunity should be prepared to meet stringent federal standards for pharmaceutical manufacturing and supply chain security. The contract’s extension into option year 4 suggests a stable and ongoing demand for Anastrozole 1 MG tablets, making this an attractive opportunity for qualified manufacturers with the capacity to deliver high-quality pharmaceutical products to federal customers. No specific set-aside requirements or special considerations are noted in the provided information, but compliance with all applicable federal regulations is mandatory throughout the contract lifecycle.
Documents9